Adverse events*
| Event | AZA | MMF |
|---|---|---|
| Death | ||
| Due to SLE | 0 | 1 |
| Due to legionellosis | 0 | 1 |
| Renal | ||
| Doubling of serum creatinine | 4 | 3 |
| End-stage renal failure | 1 | 1 |
| Infection | ||
| Benign infection | 14 | 21 |
| Herpes zoster | 5 | 4 |
| Herpes simplex | 0 | 2 |
| Cytomegalovirus | 2 | 2 |
| Chickenpox | 1 | 0 |
| Salmonella sepsis | 2 | 0 |
| Upper urinary tract infection | 0 | 2 |
| Sepsis of unknown origin | 1 | 0 |
| Streptococcus pneumonia | 0 | 1 |
| Haematological | ||
| Leucopenia | 11 | 2 |
| Leucopenia and anaemia | 1 | 0 |
| Anaemia | 2 | 0 |
| Renal haematoma | 1 | 1 |
| Psoas bleeding | 0 | 1 |
| Gastrointestinal | ||
| Nausea/diarrhoea | 8 | 8 |
| Hepatitis | 2 | 1 |
| Central nervous system | ||
| Depression | 4 | 3 |
| Psychosis | 1 | 0 |
| Headaches | 2 | 1 |
| Antimalarial retinopathy | 1 | 0 |
| Skin | ||
| Drug-induced rash | 2 | 2 |
| Alopecia | 1 | 2 |
| Gynaecological | ||
| Transient amenorrhoea | 1 | 2 |
| Gynaecological bleeding | 1 | 1 |
| Metabolic | ||
| Cushing | 1 | 3 |
| Diabetes mellitus | 1 | 0 |
| Cardiovascular | ||
| Angina pectoris | 1 | 0 |
| Cerebrovascular accident | 1 | 0 |
| Renal vein thrombosis | 1 | 0 |
| Subclavian vein thrombosis | 1 | 0 |
| Bone | ||
| Avascular osteonecrosis | 1 | 0 |
| Osteopenia | 1 | 0 |
| Rib fractures | 1 | 0 |
| Cancer | ||
| Cervix carcinoma | 2 | 0 |
| Total | 73 | 60 |
↵* Figures are number of episodes. Adverse events other than death, doubling of serum creatinine or end-stage renal failure were not recorded after drop or after the primary end point of the trial was met.